Insulet Corporation (PODD)

US — Healthcare Sector
Peers: DXCM  STE  PHG  ZBH  BIIB  LH  WAT  WST  SNN  DGX 

Automate Your Wheel Strategy on PODD

With Tiblio's Option Bot, you can configure your own wheel strategy including PODD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol PODD
  • Rev/Share 35.6981
  • Book/Share 19.5923
  • PB 12.8224
  • Debt/Equity 0.7451
  • CurrentRatio 2.8708
  • ROIC 0.1398

 

  • MktCap 17672547716.0
  • FreeCF/Share 5.9622
  • PFCF 41.9576
  • PE 72.0856
  • Debt/Assets 0.3404
  • DivYield 0
  • ROE 0.1827

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Resumed PODD TD Cowen -- Hold -- $294 Jan. 27, 2026
Downgrade PODD Barclays Overweight Equal Weight -- $274 Jan. 12, 2026
Initiation PODD Evercore ISI -- Outperform -- $370 Dec. 16, 2025
Upgrade PODD UBS Neutral Buy -- $400 Nov. 19, 2025
Resumed PODD Stifel -- Buy -- $370 Oct. 21, 2025
Resumed PODD Oppenheimer -- Outperform -- $365 Sept. 8, 2025
Initiation PODD Truist -- Buy -- $365 June 16, 2025
Initiation PODD Goldman -- Buy -- $380 May 30, 2025
Upgrade PODD Wolfe Research Peer Perform Outperform -- $350 May 13, 2025
Downgrade PODD Wolfe Research Outperform Peer Perform -- -- April 29, 2025

News

Insulet's Strong Q4 Highlights Surging Omnipod Demand And Growth Potential: Analyst
PODD
Published: February 21, 2025 by: Benzinga
Sentiment: Positive

On Thursday, Insulet Corporation PODD reported fourth-quarter adjusted EPS of $1.15, down from $1.40 a year ago but beating the consensus of $1.02.

Read More
image for news Insulet's Strong Q4 Highlights Surging Omnipod Demand And Growth Potential: Analyst
Insulet Corporation (PODD) Q4 2024 Earnings Call Transcript
PODD
Published: February 20, 2025 by: Seeking Alpha
Sentiment: Neutral

Insulet Corporation (NASDAQ:PODD ) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Company Participants June Lazaroff - Senior Director of Investor Relations Jim Hollingshead - President & Chief Executive Officer Ana Chadwick - Executive Vice President, Chief Financial Officer & Treasurer Conference Call Participants Robert Marcus - JPMorgan Jeffrey Johnson - Baird Travis Steed - Bank of America Michael Polark - Wolfe Research Issie Kirby - Redburn Atlantic Patrick Wood - Morgan Stanley Macauley Kilbane - William Blair Larry Biegelsen - Wells Fargo Marie Thibault - BTIG Mike Kratky - Leerink Partners Jayson Bedford - Raymond James …

Read More
image for news Insulet Corporation (PODD) Q4 2024 Earnings Call Transcript

About Insulet Corporation (PODD)

  • IPO Date 2007-05-15
  • Website https://www.insulet.com
  • Industry Medical - Devices
  • CEO Ashley A. McEvoy
  • Employees 3900

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.